Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Robert Keenan, MD
Arthrosi Therapeutics, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
83 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Arthrosi Investigative Site (620)
Birmingham, Alabama, United States
- Arthrosi Investigative Site (616)
Huntsville, Alabama, United States
- Arthrosi Investigative Site (680)
Peoria, Arizona, United States
- Arthrosi Investigative Site (640)
Phoenix, Arizona, United States
- Arthrosi Investigative Site (617)
Little Rock, Arkansas, United States
- Arthrosi Investigative Site (614)
Garden Grove, California, United States
- Arthrosi Investigative Site (618)
La Mesa, California, United States
- Arthrosi Investigative Site (687)
La Mesa, California, United States
- Arthrosi Investigative Site (655)
La Palma, California, United States
- Arthrosi Investigative Site (632)
Lincoln, California, United States
- Arthrosi Investigative Site (605)
Lomita, California, United States
- Arthrosi Investigative Site (675)
Long Beach, California, United States
- Arthrosi Investigative Site (603)
Santa Monica, California, United States
- Arthrosi Investigative Site (672)
Tarzana, California, United States
- Arthrosi Investigative Site (656)
Thousand Oaks, California, United States
- Arthrosi Investigative Site (660)
Aurora, Colorado, United States
- Arthrosi Investigative Site (669)
Colorado Springs, Colorado, United States
- Arthrosi Investigative Site (612)
Fort Collins, Colorado, United States
- Arthrosi Investigative Site (665)
Cooper City, Florida, United States
- Arthrosi Investigative Site (613)
Jupiter, Florida, United States
- Arthrosi Investigative Site (611)
Miami, Florida, United States
- Arthrosi Investigative Site (644)
Miami, Florida, United States
- Arthrosi Investigative Site (694)
Palmetto Bay, Florida, United States
- Arthrosi Investigative Site (615)
Sanford, Florida, United States
- Arthrosi Investigative Site (600)
Tampa, Florida, United States
- Arthrosi Investigative Site (673)
Atlanta, Georgia, United States
- Arthrosi Investigative Site (652)
Marietta, Georgia, United States
- Arthrosi Investigative Site (658)
Honolulu, Hawaii, United States
- Arthrosi Investigative Site (676)
Boise, Idaho, United States
- Arthrosi Investigative Site (634)
Meridian, Idaho, United States
- Arthrosi Investigative Site (657)
Chicago, Illinois, United States
- Arthrosi Investigative Site (648)
Melrose Park, Illinois, United States
- Arthrosi Investigative Site (678)
Indianapolis, Indiana, United States
- Arthrosi Investigative Site (679)
Overland Park, Kansas, United States
- Arthrosi Investigative Site (674)
Louisville, Kentucky, United States
- Arthrosi Investigative Site (627)
Mandeville, Louisiana, United States
- Arthrosi Investigative Site (650)
New Orleans, Louisiana, United States
- Arthrosi Investigative Site (641)
Prairieville, Louisiana, United States
- Arthrosi Investigative Site (662)
Oxon Hill, Maryland, United States
- Arthrosi Investigative Site (653)
Rockville, Maryland, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 11 Mar 2025
- Primary completion
- 30 Sept 2026
- Completion
- 31 Oct 2026
- Last update posted
- 12 May 2026
- Registered enrollment
- 750
- Registry id
- NCT06846515
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.